A phase I dose-escalation study (ISIDE-BT-1) of accelerated IMRT with temozolomide in patients with glioblastoma.

@article{Morganti2010API,
  title={A phase I dose-escalation study (ISIDE-BT-1) of accelerated IMRT with temozolomide in patients with glioblastoma.},
  author={Alessio Giuseppe Morganti and Mario Balducci and Maurizio Salvati and Vincenzo Esposito and Pantaleo Romanelli and Marica Ferro and Franco Calista and Cinzia Diges{\'u} and Gabriella Macchia and Massimo Ianiri and Francesco Deodato and Savino Cilla and Angelo Piermattei and Vincenzo Valentini and Numa Cellini and Gian Paolo Cantore},
  journal={International journal of radiation oncology, biology, physics},
  year={2010},
  volume={77 1},
  pages={92-7}
}
PURPOSE To determine the maximum tolerated dose (MTD) of fractionated intensity-modulated radiotherapy (IMRT) with temozolomide (TMZ) in patients with glioblastoma. METHODS AND MATERIALS A Phase I clinical trial was performed. Eligible patients had surgically resected or biopsy-proven glioblastoma. Patients started TMZ (75 mg/day) during IMRT and continued for 1 year (150-200 mg/day, Days 1-5 every 28 days) or until disease progression. Clinical target volume 1 (CTV1) was the tumor bed… CONTINUE READING